Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
179
resultados
Última actualización
15/06/2025 [06:58:00]
Resumen de: US2025185949A1
The present invention discloses a state-of-the-art non-invasive blood glucose monitoring system powered by radio frequency (RF) signals to determine glucose levels in the blood. The system consists of a sensor plate, which functions as an antenna, transmitting RF signals through the body and analyzing the reflection coefficient to detect changes in blood glucose concentration. A Voltage Standing Wave Ratio (VSWR) meter is integrated with the device to measure the reflection of the RF signal, which is indicative of the body's impedance mismatch due to glucose variations. The system incorporates a microcontroller, which processes the forward and reverse voltage signals obtained from the VSWR meter to calculate the reflection coefficient. In addition, a Bluetooth system is included for wireless data transmission to a secondary device, such as a smartphone or PC, where a specialized software application processes the VSWR data to estimate the blood glucose level through quadratic interpolation. The efficacy of the system is validated against standard glucometer readings, demonstrating its potential as a convenient and pain-free alternative for diabetes management and monitoring. The device's architecture and its components are designed to ensure user-friendly operation, precise measurements, and seamless integration into the user's lifestyle.
Resumen de: WO2025122639A1
Certain aspects of the present disclosure relate to methods and systems for distinguishing between temporary compression of a sensor of a continuous analyte monitoring system and failure of the sensor, such as due to detachment of the sensor. In certain aspects, an apparatus includes an analyte sensor, a temperature sensor, a memory, and a processor communicatively coupled to the memory. The processor is configured to evaluate samples of an output of the analyte sensor and samples of an output of the temperature sensor with respect to a threshold condition. If the threshold condition is met, the processor is configured to generate a signal indicating failure of the analyte sensor.
Resumen de: US2025186485A1
A hydration system including a plurality of hydration compositions for improving vascular health is provided. A hydration system comprises a first hydration composition comprising protein in an amount from 0.25 mg to 1.5 mg per kilogram of the patient's weight, sodium, potassium, and one or more essential amino acids, a second hydration composition comprising protein in an amount from 0.25 mg to 1.5 mg per kilogram of the patient's weight, sodium, potassium, and a hydrogel, a pectin based additive, a starch, or a glycerin and a third hydration composition comprising protein in an amount from 0.25 mg to 1.5 mg per kilogram of the patient's weight and at least one of electrolytes or glucose, vitamins and minerals. The hydration compositions may be formulated for oral or enteral administration.
Resumen de: US2025191743A1
Certain aspects of the present disclosure relate to methods and systems for distinguishing between temporary compression of a sensor of a continuous analyte monitoring system and failure of the sensor, such as due to detachment of the sensor. In certain aspects, an apparatus includes an analyte sensor, a temperature sensor, a memory, and a processor communicatively coupled to the memory. The processor is configured to evaluate samples of an output of the analyte sensor and samples of an output of the temperature sensor with respect to a threshold condition. If the threshold condition is met, the processor is configured to generate a signal indicating failure of the analyte sensor.
Resumen de: US2025189454A1
A Raman signal analysis device, which enables miniaturization of the device and noninvasive continuous monitoring of blood glucose level, includes a housing that forms an internal accommodation space therein; one or more light source units that are disposed within the housing and irradiate light onto a subject; a light receiving unit that obtains a Raman signal of light reflected or scattered from the subject using an optical filter array and an optical detection component array; and a processor configured to analyze biological information of the subject based on the Raman signal acquired by the light receiving unit.
Resumen de: US2025185951A1
In response to insertion of a continuous glucose monitoring (CGM) sensor into the skin of user, a CGM system compares an identifier of the sensor to any previously-stored identifiers of previously-inserted sensors. If the identifier does not match a previously-stored identifier, indicating a newly-inserted sensor, the identifier and a time stamp are stored and CGM may begin. Upon removal of the sensor, a removal time stamp is stored. If the identifier of an inserted sensor matches a previously-stored identifier, indicating a reinserted sensor, a reinsertion time is obtained and an elapsed removal time is checked to determine whether it exceeds a maximum removal time limit. If it does, CGM is halted. If it does not, CGM may continue with the reinserted sensor. Methods of tracking insertion and removal times of a CGM sensor are also provided, as are other aspects.
Resumen de: WO2025121504A1
The present invention relates to a blood glucose risk prediction and management system using blood glucose and personalized data. The blood glucose risk prediction and management system using blood glucose and personalized data includes: a user terminal which receives measurement data from a blood glucose measurement device and receives correlation factors as input; and a blood glucose management server that determines search conditions including two or more of a blood glucose measurement time, a personal state, and the correlation factors, and searches for a standard pattern among a plurality of standard patterns, compares the measurement data with the searched standard pattern to determine whether the user health state is abnormal, and if the user health state is determined to be abnormal, collects additional information and analyzes the user health state to determine whether the user health state is abnormal, and transmits an alarm for reporting the occurrence of an abnormal state to the user terminal.
Resumen de: US2025185959A1
Systems, methods and apparatus are provided, including one or more processors configured to detect a sensor calibration start event, determine outputs of one or more physiological models based on a plurality of parameters, the plurality of parameters including glucose data and insulin information, determine whether the outputs fall within a predetermined threshold, and in response to determining that the outputs fall within the predetermined threshold, execute a calibration routine.
Resumen de: US2025186695A1
The subject matter of this disclosure generally relates to a medical device system and related methodologies that leverage data associated with the use of a meal transaction application, such as an application for ordering food delivery. Data generated by the meal transaction application can be leveraged by a patient care system or application for purposes of diet or calorie logging. Alternatively or additionally, the meal transaction data can be leveraged for purposes of controlling the administration of therapy by a medication delivery system, such as an insulin infusion pump.
Resumen de: US2025186696A1
Disclosed herein are methods for establishing communication protocols between wireless devices in infusion pump systems. Infusion pump systems can include a number of components capable of wireless communication with one or more other components including an infusion pump, a continuous glucose monitoring (CGM) system, a smartphone or other remote consumer electronic device and/or a dedicated remote controller for the infusion pump. In order to ensure reliable communication of data, more than one component in a system can be capable of relaying data to another component.
Resumen de: US2025185950A1
A system and method for wireless transmission of glucose data. According to an embodiment of the present disclosure, there is provided a system, including: a glucose sensor; a beacon transmitter; and a processing circuit connected to the glucose sensor and the beacon transmitter, the processing circuit being configured to transmit a data packet, the data packet including measurement data including a measurement value, the measurement value being based on a glucose measurement.
Resumen de: EP4566644A2
The present disclosure relates to a drug-delivery device that is attachable to an infusion set hub that has been pre-inserted into a patient's body. The pre-inserted infusion set hub may be configured to deliver a primary drug such as insulin or an insulin analog. The drug-delivery device may deliver a secondary drug such as a glucagon, an NSAID, or another type of insulin or insulin analog through a cannula of the infusion hub.
Resumen de: AU2025203519A1
The present disclosure is directed to a composite implant for the sustained release of a therapeutic agent from a hydrogel matrix. The hydrogel matrix may be a cross-linked bioerodible polyethylene glycol (PEG) hydrogel with a therapeutic complex dispersed within the cross-linked bioerodible PEG hydrogel. The therapeutic complex may include a therapeutic agent in association with mesoporous silica particles. The composite implant is configured to be delivered to or implanted into an eye of a subject or patient. The composite implant may be used treat ocular disease in a subject or patient. Ocular diseases may be selected from at least one of neovascular age related macular degeneration (AMD), diabetic macular edema, or macular edema following retinal vein occlusion.
Resumen de: WO2025117512A1
A continuous analyte monitoring system includes first and second analyte sensors configured to sense analytes such as lactate and glucose in the tissue of a user. A controller Is coupled to the analyte sensors and configured evaluate first samples of outputs of the first analyte sensor and second samples of outputs of the second analyte sensor with respect to one another to determine whether the first samples and the second samples indicate compression of the tissue. If the first samples and the second samples indicate compression of the tissue, compensate for the compression of the tissue with respect to the first samples. The controller may evaluate the machine learning models using a machine learning model or a filter.
Resumen de: US2025182874A1
An insulin delivery supervisor (IDS) with a safety analysis and supervision function that can reside between the insulin request and the insulin delivery and can intercept any excessive insulin requests before the insulin was delivered. The IDS can be implemented in any system based on insulin pump or pen and will work with either SMBG or CGM modes of blood glucose monitoring.
Resumen de: AU2025203521A1
The present disclosure provides a continuous glucose monitoring device. The continuous glucose monitoring device comprises a body attachable unit configured to attach to a body; an applicator accommodating the body attachable unit, the applicator configured to guide the body attachable unit to be mounted on the body based on manipulation of a user; a housing comprising an inner case and an outer case; a plunger body movably disposed in the housing and configured to move from a first position to a second position along an insertion direction; a needle unit coupled to the plunger body; and a rotatable body being rotated based on a movement of the plunger body. The rotatable body is rotated when the plunger body moves from the first position to the second position. The rotatable body is positioned between the inner case and the plunger body to block movement of the plunger body in a withdrawal direction opposite to the insertion direction when the plunger body reaches the second position.
Resumen de: WO2025117940A1
Blood plasma samples are obtained from type 2 diabetes (T2D) patients and a concentration of F2-isoprostanes (F2I) in the sample is quantified. Plasma F2I levels assess oxidative stress levels in the patient and indicate elevated risk of T2D-associated complications including incident clinical fracture, cardiovascular complications, renal disease, etc. in the T2D cohort, independently of other risk factors. Fracture risk in the T2D population is heightened for a given bone mineral density (BMD) and is underestimated by evaluation tools such as Fracture Risk Assessment Tool (FRAX). The patient's BMD T-score can be adjusted based on F2I concentrations, capturing reductions in bone quality as well as quantity that lead to the elevated fracture risk in T2D patients. These diagnostic procedures can be effectively deployed in a patient's course of treatment merely by supplementing an existing blood panel, rather than with a separate blood draw.
Resumen de: WO2025117463A1
Disclosed herein are systems and methods for closed loop and/or partial and/or hybrid closed loop therapy that can provide adaptive personal profiles for when glucose levels are not available and/or unreliable from a continuous glucose monitor (CGM), such as, for example, during a warmup period of the CGM sensor. The profile can include temporary delivery profile such as a CGM warmup profile that is activated specifically for the particular scenario and is designed to minimize the risk of blood glucose fluctuations until the glucose levels are available and reliable, such as when the CGM sensor is warmup up and closed loop therapy based on the sensor can be activated.
Resumen de: WO2025117799A1
Embodiments described herein gradually shift a basal rate pattern for a user in time when the time on an insulin pump is changed and use glucose levels from a CGM sensor to coordinate the shift in the basal pattern with the user's actual glucose response to the changing parameters to safely transition the timing of the basal pattern as quickly as possible.
Resumen de: WO2025116766A1
The invention relates to medicine and technology, and more particularly to non-invasively detecting a change in a person's blood glucose concentration, and can be used in the creation of sensors for non-invasively checking a person's blood glucose concentration. The aim of the invention is to improve the operational efficiency of a sensor for a wrist-worn device for non-invasively checking a person's blood glucose concentration by reducing the preparation and configuration time required. The technical results of the invention include: increasing the adhesive force between a rim and the arm of a person by increasing the contact area between said rim and a wet or dry surface of the arm; reducing the energy spent on non-invasively checking a person's blood glucose concentration; and increasing the heat transfer of the sensor via the crest of the rim to the person's arm by increasing the contact area between the rim and the arm.
Resumen de: WO2025116762A1
The invention relates to medicine and technology, and more particularly to non-invasively detecting a change in a person's blood glucose concentration, and can be used in the creation of sensors for non-invasively checking a person's blood glucose concentration, as well as in the creation of socially-oriented systems for the early diagnosis of diabetes and associated diseases. The aim of the invention is to improve the operational efficiency of a sensor for a wrist-worn device for non-invasively checking a person's blood glucose concentration by reducing the operational energy consumption of the sensor by virtue of the shape of the inner surface of a rim. The technical result of the invention is that of reducing the operational energy consumption of the sensor. This reduction is achieved by virtue of the shape of the inner surface of a rim, which results in an increase in the amount of light reflected from the arm, and specifically from an artery and other vessels in the arm, and impinging on a light receiver.
Resumen de: WO2025116761A1
The invention relates to medicine and technology, and more particularly to non-invasively detecting a change in a person's blood glucose concentration, and can be used in the creation of wrist-worn devices for this purpose, as well as in the creation of socially-oriented systems for the early diagnosis of diabetes and associated diseases in the form of wrist-worn devices. The aim of the invention is to improve the operational efficiency of a wrist-worn device for non-invasively checking a person's blood glucose concentration by reducing the preparation and configuration time required. The technical result of the invention is that of reducing preparation and configuration time and, in general, reducing the time taken to perform a non-invasive check of a person's blood glucose concentration by preventing a mobile unit from moving with or along a wrist strap in relation to the radial artery of a person's arm when the person is walking or using the arm on which the device is worn.
Resumen de: WO2025116086A1
The present invention relates to technology for measuring blood glucose and glycated hemoglobin using a non-invasive PPG sensor and, more specifically, to a method and an apparatus for measuring blood glucose and glycated hemoglobin by using artificial intelligence technology in which pulse wave signals of a measurer are sensed using a PPG (pulse wave) sensor and analyzed by a machine learning algorithm to estimate blood glucose and glycated hemoglobin levels.
Resumen de: US2025176868A1
A method of calculating at least one physiological parameter using a reticulocyte production index (RPI) value can include: measuring a plurality of first glucose levels over a first time period; measuring a first glycated hemoglobin (HbA1c) level corresponding to an end of the first time period; measuring the RPI value; calculating a red blood cell elimination constant (kage) based on the RPI value; and calculating the at least one physiological parameter selected from the group consisting of: a red blood cell glycation rate constant (kgly), a red blood cell generation rate constant (kgen), and an apparent glycation constant (K), based on (1) the plurality of first glucose levels, (2) the first HbA1c level, and (3) the kage. Further, one or more related analyses (e.g., personalized-target glucose range, personalized-target average glucose, cHbA1c, and the like) can be estimated and/or adjusted based on the at least one physiological parameter.
Nº publicación: US2025176870A1 05/06/2025
Solicitante:
TRUMPF PHOTONIC COMPONENTS GMBH [DE]
TRUMPF Photonic Components GmbH
Resumen de: US2025176870A1
A device for determining a glucose concentration in an anterior chamber of a user's eye includes a VCSEL which emits laser light, and an optical element for influencing the laser light and/or an emergent light. The VCSEL and the optical element are configured such that the laser light enters the anterior chamber of the eye. The emergent light from the anterior chamber penetrates into the VCSEL. The device further includes an analysis unit that analyses a resulting self-mixing interference within the VCSEL to determine the glucose concentration.
BOPI
Sede Electrónica
